Skip Navigation



Home » Drug Information » New Medical Therapies™

Head Lice

December 26, 2011

Hatchtech released results from a phase IIb trial of DeOvo topical treatment for head lice. This double blind, randomized trial, Ha02-003, enrolled 140 subjects, ages two years and older, with head lice infestation. The subjects received a single 10-minute treatment with DeOvo (0.74% w/v or 0.37% w/v) or placebo. The primary endpoint was the proportion of all subjects who are lice free at all follow-up visits through the Day 14 visit. The primary efficacy results demonstrated a statistically significant (p<0.001) and clinically relevant outcome in both the DeOvo treatment groups (85.7% and 67.4% treatment success in the high and low dose arm, respectively) compared to the placebo group (23.4% treatment success). No serious adverse events were reported.